The use of SGLT2 inhibitors, firstly used in people with type 2 diabetes (T2D), has been proven as an effective therapeutic approach for different types of heart failure, as defined in the universal definition of heart failure (HF) in 2021 by the European Society of Cardiology (ESC) [23]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.